Safe vectors for gene therapy
US5714353A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 24, 1994 |
| Grant date | Feb 3, 1998 |
| Priority date | — |
| Expiry date | May 24, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment the sequence that is desired to be deleted is the retroviral cis-acting encapsidation sequence (E) essential for virus production in helper cells. In gene therapy embodiments, the E sequence is deleted upon reverse transcription in target cells, thus preventing spread of retroviral vectors to non-target cells in the event of infection with replication competent viruses. The retroviral vectors of the present invention thus provide safe vectors for gene therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.